This is the current revision of this page, as edited by Maxim Masiutin(talk | contribs) at 07:56, 3 January 2024(Misc citation tidying. Put the {{Short description}} template first as prescribed by MOS:ORDER.). The present address (URL) is a permanent link to this version.
Revision as of 07:56, 3 January 2024 by Maxim Masiutin(talk | contribs)(Misc citation tidying. Put the {{Short description}} template first as prescribed by MOS:ORDER.)
This gene encodes complement factor B, a component of the alternative pathway of complement activation. Factor B circulates in the blood as a single chain polypeptide. Upon activation of the alternative pathway, it is cleaved by complement factor D yielding the noncatalytic chain Ba and the catalytic subunit Bb. The active subunit Bb is a serine protease that associates with C3b to form the alternative pathway C3 convertase. Bb is involved in the proliferation of preactivated B lymphocytes, while Ba inhibits their proliferation. This gene localizes to the major histocompatibility complex (MHC class III) region on chromosome 6. This cluster includes several genes involved in regulation of the immune reaction. The polyadenylation site of this gene is 421 bp from the 5' end of the gene for complement component 2.[5]
Campbell RD, Bentley DR, Morley BJ (September 1984). "The factor B and C2 genes". Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 306 (1129): 367–78. Bibcode:1984RSPTB.306..367C. doi:10.1098/rstb.1984.0097. PMID6149579.
Yu CY (1999). "Molecular genetics of the human MHC complement gene cluster". Experimental and Clinical Immunogenetics. 15 (4): 213–30. doi:10.1159/000019075. PMID10072631. S2CID25061446.
Rawal N, Pangburn MK (March 2001). "Structure/function of C5 convertases of complement". International Immunopharmacology. 1 (3): 415–22. doi:10.1016/S1567-5769(00)00039-4. PMID11367526.
Arnason A, Larsen B, Marshall WH, Edwards JH, Macintosh P, Olaisen B, Teisberg P (August 1977). "Very close linkage between HLA-B and Bf inferred from allelic association". Nature. 268 (5620): 527–8. Bibcode:1977Natur.268..527A. doi:10.1038/268527a0. PMID889587. S2CID4262433.
Yancey KB, Overholser O, Domloge-Hultsch N, Li LJ, Caughman SW, Bisalbutra P (March 1992). "Human keratinocytes and A-431 cells synthesize and secrete factor B, the major zymogen protease of the alternative complement pathway". The Journal of Investigative Dermatology. 98 (3): 379–83. doi:10.1111/1523-1747.ep12499812. PMID1545147.
Davrinche C, Abbal M, Clerc A (1991). "Molecular characterization of human complement factor B subtypes". Immunogenetics. 32 (5): 309–12. doi:10.1007/bf00211644. PMID2249879. S2CID13698345.
Wu LC, Morley BJ, Campbell RD (January 1987). "Cell-specific expression of the human complement protein factor B gene: evidence for the role of two distinct 5'-flanking elements". Cell. 48 (2): 331–42. doi:10.1016/0092-8674(87)90436-3. PMID3643061. S2CID32752642.
Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene. 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID8125298.
Mejía JE, Jahn I, de la Salle H, Hauptmann G (January 1994). "Human factor B. Complete cDNA sequence of the BF*S allele". Human Immunology. 39 (1): 49–53. doi:10.1016/0198-8859(94)90100-7. PMID8181962.